A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Must have received: rituximab (rituximab)

Participants have previously received rituximab Treatment (unless rituximab is intolerant)

Cannot have received: biologic targeted therapy

Treatment with biologic targeted therapy or anti-tumor immunotherapy within 4 weeks prior to the first dose of YK012

Cannot have received: anti-tumor immunotherapy

Treatment with biologic targeted therapy or anti-tumor immunotherapy within 4 weeks prior to the first dose of YK012

Cannot have received: chemotherapy

Participants who have received chemotherapy within 4 weeks prior to the first dose of YK012

Cannot have received: small molecule targeted agent

Participants who have received small molecule targeted agents within 2 weeks or 5 half-lives (whichever is longer) prior to the first dose of YK012

Cannot have received: investigational agent

Participants who have received other investigational agents within 4 weeks or 5 half-lives (whichever is shorter) prior to the first dose of YK012

Cannot have received: radiation therapy

Participants who have received radical/extensive radiotherapy within 4 weeks prior to the first dose of YK012, or local palliative radiotherapy within 2 weeks prior to the first dose of YK012, or acute toxicity induced by previous radiotherapy have not recovered to grade ≤1

Cannot have received: autologous stem cell transplant

Participants who have received autologous HSCT within 12 weeks prior to the first dose of YK012

Cannot have received: allogeneic stem cell transplant

Participants who have received allogeneic HSCT or organ transplant

Cannot have received: organ transplant

Participants who have received allogeneic HSCT or organ transplant

Cannot have received: CAR-T cell therapy

Participants who have received chimeric antigen receptor T cell (CAR-T) immunotherapy